Liver regeneration by a population of midzone-located mesenchymal-hepatocyte hybrid cells

Curation statements for this article:
  • Curated by eLife

    eLife logo

    eLife assessment

    This study is partly useful as it corroborates what is already known about the elevated proliferation capacity of mid lobular hepatocytes in liver regeneration. Lineage tracing and scRNAseq studies are powerful for the investigation of such heterogeneous hepatocyte proliferation capacity. Nevertheless, based on experimental limitations, incomplete method description and inadequate data analyses the presented data are insufficient to support the proposed conclusions of a mesenchymal-hepatocyte hybrid population in the murine liver.

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

Regenerative medicine relies on deep understanding of the mechanisms of organ repair and regeneration. The liver, an organ with critical metabolic functions carried out by hepatocytes located in zones 1-3 of liver lobules, has the capacity to fully regenerate itself, which is mainly attributable to midzone hepatocytes. Yet, how differentiated midzone hepatocytes execute transzone regeneration and quickly recover most of the liver mass remains a myth. Here, we uncover a mesenchymal-hepatocyte population (13.7% of total hepatocytes) that are derived from Twist2-lineage EpCAM + progenitors, midzone-located, highly polyploidy, and equipped with great mitogenic and migratory capabilities to the detriment of metabolism. They regenerate about 50% of new hepatocytes and repopulate zones 1 and 3 in liver regeneration. Mechanistically, expansion of these cells is negatively controlled by Notch1 signaling. This study has thus uncovered a hepatocyte subpopulation with great proliferation potential and important mechanisms of liver regeneration.

Article activity feed

  1. eLife assessment

    This study is partly useful as it corroborates what is already known about the elevated proliferation capacity of mid lobular hepatocytes in liver regeneration. Lineage tracing and scRNAseq studies are powerful for the investigation of such heterogeneous hepatocyte proliferation capacity. Nevertheless, based on experimental limitations, incomplete method description and inadequate data analyses the presented data are insufficient to support the proposed conclusions of a mesenchymal-hepatocyte hybrid population in the murine liver.

  2. Reviewer #1 (Public Review):

    Summary:

    This valuable study by Gui Yu and colleagues aims to investigate the function of a subtype of hepatocyte, which expressed Twist2 at some point in its lineage. First, using reporter mice, they show that hepatocytes can be labelled using Twist2-cre mice. Importantly, Twist2-cre also labels liver mesenchymal cells. Using scRNA seq of P1 and P14 Twist2-Cre tomato-labelled cells, they identify both mesenchymal cells and hepatocytes, and (using trajectory analyses) propose that Twist-traced hepatocytes and mesenchymal cells are derived from Epcam+ progenitors. The authors propose that the Twist2-traced hepatocytes occupy the midzone, and are polyploid. Using partial hepatectomy and Ccl4 as models for regeneration, the authors show that, after insult, there is an increase in Twist2-Tomato+ cells, which are more proliferative. Next, the authors propose that Notch signaling is suppressed during regeneration (based on the downregulation of HES1 protein in midzone hepatocytes during regeneration). They therefore knock out Notch1 in Twist2-expressing cells and show that this leads to hepatocyte proliferation (but fewer liver lobes) in homeostatic conditions. Finally, the authors also interfere with mTor and VEGF signaling and show that both interventions suppresses the excess hepatocyte proliferation in Twist2-conditional Notch1-knockout mice.

    Strengths:

    Overall, the data show that Twist2 is expressed at some point during hepatocyte development or homeostasis, and that Notch1 in hepatocytes or mesenchymal cells plays a role in limiting homeostatic hepatocyte proliferation.

    Weaknesses:

    The study relies heavily on the use of Twist2-Cre mice, which labels both mesenchymal cells and hepatocytes. Several experiments on hepatocytes (such as scRNA seq or bulk RNA seq) could be confounded by doublets or contamination with mesenchymal cells.

  3. Reviewer #2 (Public Review):

    Summary:

    There are two potential contributions made by this study, both of which are not fully supported by the data presented. First, that Twist-positive hepatocytes in the midlobular zone are derived from Twist2-expressing cells in embryonic livers via intermediate EpCAM-expressing cells. Second, that there is a population of hepatocytes with mesenchymal features that drive regeneration after various injuries. The concept that mid-lobular hepatocytes are more regenerative in adult injury settings has already been established and this paper further supports that body of knowledge.

    Strengths:

    There are copious scRNA-seq data that are supportive of the claims, but these analyses were not definitive.

    Weaknesses:

    1. There is not sufficient evidence to support the following assertion: "markers identified a mesenchymal-hepatocyte hybrid population (13.7% of total hepatocytes) that express signature genes of both lineages." Twist-Cre reporter mice mark hepatocytes and mesenchymal populations, but it is not clear whether or not this means that the hepatocyte population labeled by Twist is mesenchymal. It is very possible for hepatocytes to express mesenchymal genes without being a true hybrid population. There is not much evidence that zone 2 cells are a mix of hepatocyte and mesenchymal. The idea of a hybrid population needs to be defined. The definition probably needs to involve the concept that hybrid cells must have morphologic or functional features of mesenchymal cells, rather than just expressing some genes from each cell type.

    Related to this, the authors claim that co-expression of Twist and EpCAM in E10.5 liver cells might support the existence of a hepatomesenchymal cell type. This is possible, but one should note that adult hepatocytes can express EpCAM, especially during ductular reactions, so it is not necessarily a mesenchymal marker per se.

    2. The authors assert several times that Twist-Cre mice appear to have no effect on overall liver regeneration phenotypes. They use this to suggest a lack of an effect for heterozygous deletion of Twist by the Cre allele. It is still possible for these mice to have altered lineage tracing results. It is very difficult to rule this out. For example, Axin2-CreER mice did not have any overt liver function or regeneration phenotypes, but the lineage tracing results from these mice differed from other CreER mice.

    3. The central problem with this study is that the authors use a Cre strain and not a CreER strain. With a Cre strain, there could be new labeling of Twist-positive cells at multiple later time points. Thus, it is very difficult to assert that the Tomato-positive population at later time points are really descendants of the originally labeled population. It is very difficult to interpret the results of Cre-based lineage tracing experiments.

    With this technical limitation in mind, I do not think that there is enough evidence to support the assertion made on page 6: "These findings suggest that EpCAMlow progenitor cells give rise to hepatocytes and MCs." The authors use scRNA-seq trajectory analysis to come to the conclusion that mesenchymal cells give rise to hepatocytes between p1 and p14. Much more evidence is needed before the authors can arrive at this conclusion. It is much more likely that midlobular hepatocytes arise from other hepatocytes. To support their arguments, the authors would have to use a CreER line that exclusively labels mesenchymal cells in the liver, then lineage traces them until p14 to determine if they become hepatocytes. Without such an experiment, I do not think the current experiments are interpretable.

    4. The injury experiments are again limited in their interpretability because they do not use CreER. It is very possible that Twist is turned on after CCl4 or surgical injury, and thus new hepatocytes might activate Tomato. It is unclear if previously Tomato-positive midzone hepatocytes were proliferating to increase the Tomato positive population. The authors use expression-based studies to argue against ectopic activation of Twist, but it is very difficult to exclude Cre activation using these types of studies.